Eli Lilly Pharma CDK4 & 6 inhibitor Weixuan (Abexili tablets) early breast cancer indications were officially launched in China recently.
As the first and only CDK4 & 6 inhibitor approved for use in patients with early-stage breast cancer in China, Vixel (abexili tablets) was approved by NMPA in December 2021 for adjuvant therapy in combination with endocrine therapy (tamoxifen or aromatase inhibitors) for adjuvant therapy in adults with hormone receptor (HR), human epidermal growth factor receptor 2 (HER2) negative, lymph node-positive, high risk of recurrence and Ki-67≥ 20% of adults with early-stage breast cancer. This is another new indication for the market after Vesite (Abexilide tablets) is used to treat locally advanced or metastatic breast cancer of HR+, HER2-.
Early Breast Cancer Indications Roundtable Discussion
Breast cancer has become the world's first incidence of cancer, according to the International Agency for Research on Cancer statistics, in 2020, China's new breast cancer cases about 416,000, about 117,000 deaths, accounting for about 17.1% of global breast cancer deaths. It is estimated that 90% of breast cancers are diagnosed in the early stages. The most common subtype is HR+, HER2-type, which accounts for about 70% of the total number of breast cancer patients. Endocrine therapy is the standard adjuvant treatment regimen for patients with HR+, HER2-early-stage breast cancer, but 20% of patients will still develop relapse metastasis, and patients with high-risk clinical and/or pathological features will have a higher risk of recurrence and require new treatment regimens to further reduce the risk of recurrence.
As a highly selective CDK4 & 6 inhibitor, Visco (Abexili tablets) is the first and only CDK4 & 6 inhibitor approved for HR+, HER2- with lymph node-positive, high risk of recurrence, Ki-67≥ 20% of patients at high risk of early-stage breast cancer. Weixue (abexili tablets) combined with endocrine therapy can significantly reduce the risk of recurrence and distant metastasis in such high-risk patients, and has been unanimously recommended by authoritative guidelines at home and abroad. After the new indications of Weixuan (Abexili tablets) are listed in China, it will open a new era of adjuvant treatment for high-risk patients with HR+, HER2-early breast cancer, and bring more hope for cure for the majority of early-stage breast cancer patients.
"On the eve of this year's International Women's Day, we are pleased to hear that the indications for early breast cancer of Weixue (Abecilli tablets) are officially available in China. This is undoubtedly the best holiday gift for the majority of sisters suffering from breast cancer," said Professor Shi Anli, honorary chairman of the Rehabilitation Branch of the Chinese Anti-Cancer Association and chairman of the Beijing Aipu Cancer Patient Care Foundation. We look forward to opening a new chapter in China's breast cancer treatment and turning the crisis between the patients and sisters. ”
[Reporter] Ou Xujiang
【Author】 Ou Xujiang
Healthy living circle